

Special Issue

Cardiovascular Care in Transition: From Biomedical Engineering to Digital Medicine

Message from the Guest Editors

Cardiovascular disease represents the most frequent cause of death in the Western world due to non-communicable entities. During the previous century, technological innovations led to advances both in the pharmaceutical armamentarium and interventional cardiology and electrophysiology which transformed clinical practice as we knew it. Structural interventional procedures including—but not restricted to—transcatheter heart valve interventions are a prominent example of this evolving transformation. The situation is similar in the field of interventional electrophysiology, with three-dimensional electro-anatomical mapping leading a true paradigm shift in the treatment of arrhythmias. Applications of artificial intelligence utilizing machine and deep learning algorithms are already present in the field of medical research, covering a wide range of targets from disease diagnosis, staging and treatment to healthcare logistics. The present Special Issue aims to explore pathophysiological, diagnostic, and treatment aspects of biomedical engineering and digital health in the field of cardiovascular medicine.

Guest Editors

Dr. Dimitrios A. Vrachatis

Prof. Dr. Spyridon G. Deftereos

Prof. Dr. Theodore G. Papaioannou

Deadline for manuscript submissions

closed (31 December 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/147574

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).